-+ 0.00%
-+ 0.00%
-+ 0.00%

Need To Know: The Consensus Just Cut Its Beam Therapeutics Inc. (NASDAQ:BEAM) Estimates For 2027

Simply Wall St·11/18/2026 10:24:59
语音播报

Market forces rained on the parade of Beam Therapeutics Inc. (NASDAQ:BEAM) shareholders today, when the analysts downgraded their forecasts for next year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

Following the latest downgrade, the current consensus, from the 14 analysts covering Beam Therapeutics, is for revenues of US$26m in 2027, which would reflect a sizeable 82% reduction in Beam Therapeutics' sales over the past 12 months. Before the latest update, the analysts were foreseeing US$30m of revenue in 2027. It looks like forecasts have become a fair bit less optimistic on Beam Therapeutics, given the measurable cut to revenue estimates.

Check out our latest analysis for Beam Therapeutics

earnings-and-revenue-growth
NasdaqGS:BEAM Earnings and Revenue Growth November 18th 2026

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that sales are expected to reverse, with a forecast 75% annualised revenue decline to the end of 2027. That is a notable change from historical growth of 15% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 21% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Beam Therapeutics is expected to lag the wider industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for Beam Therapeutics next year. They're also anticipating slower revenue growth than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on Beam Therapeutics after today.

Unanswered questions? At least one of Beam Therapeutics' 14 analysts has provided estimates out to 2028, which can be seen for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.